ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO350

Efficacy of the Combination of Acetazolamide with Loop Diuretics vs. Double-Dose Loop Diuretics for Decongestion in CKD Patients: A Randomized Controlled Trial

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical

Author

  • Sriswasdi, Jiranat, Phramongkutklao Hospital, Bangkok, Thailand
Background

The combination of acetazolamide and loop diuretics in the setting of hospitalized heart failure has shown promising results in improving diuresis and decongestion. However, the effectiveness of this combination in chronic kidney disease (CKD) with volume overload has yet to be determined.

Methods

CKD patients with fluid overload, confirmed by bioimpedance spectroscopy, were allocated to receive oral acetazolamide 250 mg/day plus furosemide or a doubled dose of furosemide. Volume status, changes of body fluid compartment from body composition monitoring, and urinary sodium were evaluated at baseline, 2, and 4 weeks. The main outcome was the proportion of body weight reduction (> 2 kg and 5%) and mean change of body weight at 2 weeks.

Results

Fifty-two CKD patients with an estimated glomerular filtration rate of 38 mL/min/1.73 m2 were included. Body weight reduction > 2 kg at week 2 (40.7% vs. 12%, risk ratio (RR) 3.39, 95% CI 1.06-10.7) and body weight reduction > 5% at week 2 (25.9% vs 0% RR 2.25, 95%CI 1.62-3.12) significantly occurred in the combination group compared to the doubled-dose group. Additionally, mean difference of body weight reduction between combination group and doubled dose group was -1.37 kg, 95%CI -2.498, -0.242). The combination group showed lower rates of alkalosis and hypokalemia at 4 weeks. No serious adverse events were found in either group.

Conclusion

Adding acetazolamide to loop diuretics ameliorates volume overload in CKD patients without significant or serious side effects.

Primary outcome
Body weight reduction at week 2

Funding

  • Government Support – Non-U.S.